651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II

A CD38xCD28 Costimulatory Bispecific Antibody Demonstrates Potent Preclinical Combinatorial Activity with a BCMAxCD3 T Cell-Engager

A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

Abundance of C1q Expressing Macrophages Promotes Resistance to Modern Therapy

Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide

CREB1 and TXNIP Regulate Autophagy and Unfolded Protein Response in Multiple Myeloma

Characterization of Linvoseltamab’s BCMA Binding Epitope and Efficacy Against BCMA Mutations in Relapsed/Refractory Multiple Myeloma

Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome

Comprehensive Assessment of Immunoglobulin Translocation Detection in Multiple Myeloma By Whole Genome Sequencing

Comprehensive Translatomic Analysis of Multiple Myeloma Unveils Novel Insights into Disease Pathogenesis

Critical Roles of LILRB4 in Promoting PIM Kinase Mediated Cell Proliferation and Tumorigenesis in Multiple Myeloma

Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis

IMiDs and Celmods Enhance Antigen Presentation Via MHC Class 1 – a Potential Novel Immunostimulatory Effect

Improving Anti-BCMA CAR-T Functionality with Novel Celmods in Multiple Myeloma

Inhibition of Endoplasmic Reticulum Associated Degradation Is Cytotoxic to Relapsed Refractory Multiple Myeloma through Altered Proapoptotic Signaling

Lipid Nanoparticle-Mediated Combinational mRNA Vaccine for Multiple Myeloma: The Next Stage of Cancer Immunotherapy

Mast Cells Support Multiple Myeloma Survival and Engraftment through Secreted Factors

Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma

Multiple Myeloma Persister Cells Surviving Bispecific Antibodies and CAR-T Cells Exhibit New CD45+ Expression

Novel NOTCH1 Effector NFIL3 Is a Therapeutic Target to Combat Drug Resistance and Improve Patient Outcomes in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma

PSMC2 Overexpression Promotes Synthetic Lethality Sensitizing Multiple Myeloma Cells to p97 Inhibition

Preclinical Development of a Novel Pan-RAS Inhibitor Against Relapsed/Refractory Multiple Myeloma

Role of Ras-Related C3 Botulinus Toxin Substrate 1 in p53-Related Proliferation and Drug Sensitivity in Multiple Myeloma

Targeting of the CD161 Inhibitory Receptor Enhances Bone Marrow-Resident Memory CD8+ T Cell-Mediated Immunity Against Multiple Myeloma

Targeting the PI3K/AKT Pathway and Fatty Acid Synthase in AL Amyloidosis: Mechanistic Insights and Therapeutic Implications

The Immune Inhibitory Hematopoietic Adaptor Protein Hacs1(Sly2) Suppresses the Proinflammatory Macrophage Function Contributing to Multiple Myeloma Progression

The c-MAF/SLP76 Axis Modulates Immune Evasion and Drives Malignancy in Multiple Myeloma Via Epigenetic Reprogramming

Voltage-Dependent Anion Channel 2 Controls Mitochondrial Priming through BAK Stabilization in Multiple Myeloma